Elmind Capital LP Purchases New Holdings in Septerna, Inc. $SEPN

Key Points

• Elmind Capital LP acquired 49,444 Septerna shares during the second quarter, valued at approximately $1.66 billion according to its SEC filing, representing about 0.11% of the company.
• Analyst sentiment remains broadly positive: Septerna has a “Moderate Buy” consensus rating and a $52.44 average price target, with several firms recently raising targets to between $48 and $62.
• Septerna shares opened at $41.30, while the company reported better-than-expected quarterly results of a $0.29 loss per share and $26.75 million in revenue. Insiders, however, sold 61,030 shares worth approximately $2.33 million over the past 90 days.

Elmind Capital LP acquired a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 49,444 shares of the company's stock, valued at approximately $1,655,880,000. Elmind Capital LP owned approximately 0.11% of Septerna as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in SEPN. Deutsche Bank AG lifted its stake in shares of Septerna by 5.3% during the fourth quarter. Deutsche Bank AG now owns 14,879 shares of the company's stock valued at $415,000 after acquiring an additional 744 shares during the period. Global Retirement Partners LLC bought a new stake in Septerna during the 4th quarter worth about $35,000. JPMorgan Chase & Co. raised its holdings in Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company's stock worth $107,000 after purchasing an additional 1,315 shares during the last quarter. PharVision Advisers LLC lifted its position in Septerna by 17.5% during the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company's stock valued at $224,000 after purchasing an additional 1,780 shares during the period. Finally, Nuveen LLC grew its position in shares of Septerna by 7.7% during the 4th quarter. Nuveen LLC now owns 25,798 shares of the company's stock worth $719,000 after buying an additional 1,837 shares during the period.

Analysts Set New Price Targets

SEPN has been the topic of a number of recent research reports. HC Wainwright raised their price objective on shares of Septerna from $40.00 to $60.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. JonesTrading lifted their price objective on Septerna from $43.00 to $62.00 and gave the stock a "buy" rating in a research note on Thursday, August 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Septerna in a report on Friday, July 17th. Guggenheim increased their target price on Septerna from $45.00 to $51.00 and gave the company a "buy" rating in a research note on Tuesday, August 11th. Finally, JPMorgan Chase & Co. boosted their target price on Septerna from $38.00 to $48.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $52.44.

Septerna Stock Up 1.9%

Shares of NASDAQ SEPN opened at $41.30 on Wednesday. Septerna, Inc. has a twelve month low of $11.70 and a twelve month high of $51.10. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -76.48 and a beta of 2.29. The company's fifty day moving average is $37.06 and its 200-day moving average is $30.54.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.14. The business had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. On average, research analysts anticipate that Septerna, Inc. will post -1.41 EPS for the current fiscal year.

Insider Transactions at Septerna

In other news, SVP Daniel D. Long sold 3,334 shares of Septerna stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $34.47, for a total transaction of $114,922.98. Following the transaction, the senior vice president owned 96,412 shares in the company, valued at $3,323,321.64. The trade was a 3.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Samira Shaikhly sold 2,178 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $35.18, for a total value of $76,622.04. Following the sale, the insider directly owned 793 shares of the company's stock, valued at approximately $27,897.74. The trade was a 73.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 61,030 shares of company stock valued at $2,329,666 over the last 90 days. 5.80% of the stock is owned by company insiders.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.

Want to see what other hedge funds are holding SEPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Septerna, Inc. (NASDAQ:SEPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source